TP53 and leukemia: In other words, the minor clone with TP53 mutant already emerged 41 months before the development of therapy-related leukemia; the minor clone of cells escaped subsequent treatments, expanded and finally transformed to AML accompanied by complex cytogenetic abnormalities.35 Taken together, TP53 mutations are quite stable during AML progression.